Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.

Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.

Woodrick discusses how his team monitors subclinical progression and the multidisciplinary consortium supporting care.

Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.

Richardson discusses the safety profile of CD19 CAR-T, the debate over B cell targets, and more.

Carrie Richardson, MD, discusses what early CAR-T trial data mean for reversing damage and redefining remission in systemic sclerosis.

A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.